PDCD1 and melanoma: Three studies in Science support the idea that the composition of the gut microbiome modulates the response to immunotherapy in patients with epithelial tumors, including non-small cell lung (103) and kidney cancers (104) and melanoma (105) by blocking anti-PD-1 or PD-1 ligand 1(PD-L1).